Enhancement of Anti-tumor Immune Response and Decrease of Recurrence Rate of Cervical Cancer by Low Dose Metronomic Chemotherapy of Cisplatin

Objective To explore the effect of low dose metronomic chemotherapy of cisplatin on specifi c anti-tumor immune response and recurrence rate of cervical cancer. Methods Establish C57BL/6 mouse tumor model with TC-1 cells was established, the mice were divided into 3 groups (n=5) (control, low dose and high dose group). The tumor growth curve was drawn and the HPV-E7 specifi c CD8+ T cells number in PBMC were determined. The tumor model establishment, grouping and treatment were same as above, after 7 days treatment, the tumor was removed and the TC-1 cells were reinjected in the contralateral hypogastrium after 2 days of surgery. The tumor recurrence rate and survival rate were checked. Results (1)The antitumor effect was similar after low dose or high dose cisplatin treatment.(2) The HPV-E7 specifi c CD8+T cells in low dose group were significantly higher than that in control or high dose group.(3)The tumor recurrence rate in the low dose group was lower than that in control or high dose group.(4)The survival rate in low dose group was higher than that in control or high dose group. Conclusion Low dose metronomic chemotherapy of cisplatin can inhibit tumor growth effectively, through enhancing specific antitumor immune response, decrease the recurrence of tumor and increase the host survival rate in a certain extent.